Voronoi

Voronoi, founded in 2015 in Songdo, Incheon, develops precision kinase-targeted therapies; it does not manufacture finished drugs but advances its own candidates into early clinical stages and monetizes them through licensing.

Its strategy is to focus self-developed pipelines on early clinical development and then license them out, with no finished-product manufacturing and revenue arising from licensing.

Revenue is therefore lumpy, concentrated in periods when upfront or milestone payments are received, and per securities data providers sales are effectively a single line of targeted-therapy service revenue, with revenue generated in the targeted-therapy service segment.

The core asset is Voronomics, a discovery platform combining laboratory data with artificial intelligence, where target selectivity and high blood-brain barrier penetration are presented as the competitive axes.

Clinical-stage assets center on VRN11 for EGFR-mutant non-small cell lung cancer, VRN10 for HER2-driven solid tumors, and VRN07 (ORIC-114), licensed to ORIC Pharmaceuticals of the United States.

The 2020 license of VRN07 to Nasdaq-listed ORIC carried a total deal size of 621 million dollars with a 13 million dollar upfront payment. The company has completed five licensing transactions including those with ORIC, and also pursued commercialization by selling technology assets to Anvia.

That said, Pyramid returned rights to VRN08 in November 2023, and in April 2024 METiS and Fresh Tracks terminated their VRN04 and VRN02 agreements respectively, showing that a signed license does not automatically translate into durable income.

Competitively, VRN11 targets the resistance setting after AstraZeneca's Tagrisso (osimertinib) as well as the first-line market, while VRN10 competes against the established HER2-directed drug class.

Consolidated revenue in 2025 was 7.5 billion won, ending the zero-revenue stretch of 2023 and 2024, yet the operating loss widened to 54.4 billion won from 36.3 billion won in 2024 and 31.3 billion won in 2023, with an operating margin of -723.9%.

Net loss attributable to owners grew to 42.7 billion won in 2025 from 32.6 billion won in 2024, and operating cash flow of -72.1 billion won was more than twice as negative as 2024's -29.1 billion won.

Compared with 2022, when revenue was 9.8 billion won and the operating loss 17.9 billion won (operating margin -182.9%), the cost structure has clearly entered a different phase.

Quarterly, revenue was 3.4 billion won with a 10.2 billion won operating loss in the second quarter of 2025 and 4.1 billion won with a 13.6 billion won loss in the third, before revenue effectively vanished to 0.02 billion won in the fourth quarter as the operating loss grew to 16.2 billion won.

The fourth-quarter 2025 net loss attributable to owners of 4.3 billion won was smaller than the operating loss, reflecting non-operating items and underscoring high earnings volatility.

In 2026, with no revenue in either the first or second quarter, operating losses widened to 22.0 billion won and 29.3 billion won, making the second quarter of 2026 the largest quarterly loss in the period shown.

Over the most recent four quarters (third quarter 2025 through second quarter 2026), the cumulative net loss attributable to owners was 69.1 billion won, which is large relative to total equity of 103.8 billion won at the end of 2025, indicating rapid consumption of the equity buffer.

On the balance sheet, the debt-to-equity ratio rose from 10.9% in 2024 to 65.0% in 2025, reflecting mezzanine financing raised to fund expanded in-house trials.

Press coverage based on the semi-annual report noted the company raised a total of 131.5 billion won, including 50 billion won of convertible bonds, 36 billion won of exchangeable bonds and 45.6 billion won via a price return swap, of which 62.5 billion won had been used by the end of June 2026, leaving roughly 69 billion won unused, explaining how the widening losses are being funded.

EGFR-mutant non-small cell lung cancer is a market where the third-generation agent Tagrisso has established the first-line standard, leaving the treatment of subsequent resistance mutations as a core unmet need.

EGFR C797S is the representative resistance mutation arising after osimertinib therapy, and with no established standard of care in that setting, multiple fourth-generation EGFR inhibitors are being developed in parallel.

On market size, April 2026 press coverage cited an assessment that commercialization could address an EGFR C797S non-small cell lung cancer market of roughly 1 trillion won, and that entry into the first-line setting could address a 15 trillion won market.

However, the treatment-naive segment is where Tagrisso anchors the standard of care, so early response rates alone are considered insufficient; depth of tumor shrinkage, progression-free survival and control of brain metastases must all be demonstrated.

Central nervous system activity is a key differentiator here: preclinically, VRN11 blood-brain barrier penetration was reported at 100% in both mice and rats, versus 28.9% and 21% for Tagrisso.

In HER2-driven solid tumors, established competitors such as Tukysa, Hernexeos and Hyrnuo are already entrenched, requiring mechanistic differentiation.

Across Korean drug-discovery biotechs, there is a visible shift away from monetizing assets via very early licensing toward running trials in-house to raise value before negotiating, a transition that enlarges potential deal value but shifts cost and failure risk onto the company. Voronoi is likewise viewed as having entered the spending phase of its own clinical validation model.

VRN11's global trial footprint is expanding rapidly. According to a September 8, 2026 disclosure, the VRN11 global phase 1b/2 protocol was approved by Malaysia's National Pharmaceutical Regulatory Agency, adding a fourth country after Australia, Hong Kong and Singapore.

An amendment approval from Australia's Human Research Ethics Committee brought treatment-naive EGFR-mutant patients into the eligible population, and the global multi-center phase 1/2 study targets 391 patients.

On data, WCLC 2026 reported objective responses in all six C797S-mutant patients dosed at 160mg or above, with median progression-free survival of 11 months in that cohort, and the company stated that intracranial disease control was 100% among 19 patients with brain metastases, with serious adverse events rare.

For VRN10, phase 1a was being run in Korea and Australia with a stated plan to enter phase 1b/2 in 2026, and the company said that its AACR 2026 presentation confirmed a mechanism inducing HER2 internalization and degradation that increases payload release when combined with Enhertu.

Organizationally, the company created a chief medical officer role and recruited a clinical development executive from a global pharmaceutical company to build out global trial capability.

On the partner side, ORIC disclosed in 2025 a plan to complete the ORIC-114 phase 1/2 in 2026 and to start a phase 3 in first-line non-small cell lung cancer the same year, with a filing target of 2028.

No numerical company guidance is publicly confirmed, and revenue is expected to remain driven by the timing of licensing and milestone events.